WO2012178184A3 - Removable protective shell for imaging agents and bioactive substances - Google Patents

Removable protective shell for imaging agents and bioactive substances Download PDF

Info

Publication number
WO2012178184A3
WO2012178184A3 PCT/US2012/044052 US2012044052W WO2012178184A3 WO 2012178184 A3 WO2012178184 A3 WO 2012178184A3 US 2012044052 W US2012044052 W US 2012044052W WO 2012178184 A3 WO2012178184 A3 WO 2012178184A3
Authority
WO
WIPO (PCT)
Prior art keywords
imaging agents
nanoparticles
protective shell
removable protective
bioactive substances
Prior art date
Application number
PCT/US2012/044052
Other languages
French (fr)
Other versions
WO2012178184A2 (en
Inventor
Travis J. Williams
Andy Y. Chang
Original Assignee
Children's Hospital Los Angeles
University Of Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children's Hospital Los Angeles, University Of Southern California filed Critical Children's Hospital Los Angeles
Publication of WO2012178184A2 publication Critical patent/WO2012178184A2/en
Publication of WO2012178184A3 publication Critical patent/WO2012178184A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1878—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating
    • A61K49/1881—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating wherein the coating consists of chelates, i.e. chelating group complexing a (super)(para)magnetic ion, bound to the surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides nanoparticles for delivery of imaging agents, drugs, and other molecules, such as genetic material. The nanoparticles have a core structure comprising the imaging agent and/or drug, and a shell structure that allows for water solubility. The shell structure further provides a barrier with limited water permeability that protects the core. The nanoparticles can be induced to release their cargo by treatment with ultrasound. Methods of delivering drugs and imaging agents are also provided, whereby the nanoparticles are delivered to tissues of interest in a substantially inert form, then activated using ultrasound to release the drugs or imaging agents.
PCT/US2012/044052 2011-06-23 2012-06-25 Removable protective shell for imaging agents and bioactive substances WO2012178184A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161500585P 2011-06-23 2011-06-23
US61/500,585 2011-06-23

Publications (2)

Publication Number Publication Date
WO2012178184A2 WO2012178184A2 (en) 2012-12-27
WO2012178184A3 true WO2012178184A3 (en) 2014-05-08

Family

ID=47423269

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/044052 WO2012178184A2 (en) 2011-06-23 2012-06-25 Removable protective shell for imaging agents and bioactive substances

Country Status (1)

Country Link
WO (1) WO2012178184A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6559644B2 (en) * 2001-05-30 2003-05-06 Insightec - Txsonics Ltd. MRI-based temperature mapping with error compensation
US20050214379A1 (en) * 2004-01-02 2005-09-29 Sandro Mecozzi Encapsulation of chemical compounds in fluorous-core and fluorous-inner-shell micelles formed from semifluorinated-block or fluorinated-block copolymers
US20060293396A1 (en) * 2005-01-14 2006-12-28 Eastman Kodak Company Amine polymer-modified nanoparticulate carriers
US20070243259A1 (en) * 2006-04-17 2007-10-18 Hsing-Wen Sung Nanoparticles for protein/peptide delivery and delivery means
US20080044746A1 (en) * 1998-11-20 2008-02-21 Anderson Richard R Permanent, removable tissue markings
US20100068522A1 (en) * 2008-08-07 2010-03-18 Nanoco Technologies Limited Surface Functionalised Nanoparticles

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080044746A1 (en) * 1998-11-20 2008-02-21 Anderson Richard R Permanent, removable tissue markings
US6559644B2 (en) * 2001-05-30 2003-05-06 Insightec - Txsonics Ltd. MRI-based temperature mapping with error compensation
US20050214379A1 (en) * 2004-01-02 2005-09-29 Sandro Mecozzi Encapsulation of chemical compounds in fluorous-core and fluorous-inner-shell micelles formed from semifluorinated-block or fluorinated-block copolymers
US20060293396A1 (en) * 2005-01-14 2006-12-28 Eastman Kodak Company Amine polymer-modified nanoparticulate carriers
US20070243259A1 (en) * 2006-04-17 2007-10-18 Hsing-Wen Sung Nanoparticles for protein/peptide delivery and delivery means
US20100068522A1 (en) * 2008-08-07 2010-03-18 Nanoco Technologies Limited Surface Functionalised Nanoparticles

Also Published As

Publication number Publication date
WO2012178184A2 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
IL253000B (en) Tricyclic pyrazolyl compounds, their use in the preparation of medicaments for the treatment of cancer and pharmaceutical compositions comprising them
MX2013012458A (en) Intravascular delivery of nanoparticle compositions and uses thereof.
MY172519A (en) Solid polymeric controlled release nanoparticle
IL232308A (en) C0mpounds as modulators of atp-binding cassette transporters, pharmaceutical compositions comprising them and their use in the preparation of medicaments for treating diseases and processes for preparation thereof
HK1212618A1 (en) Drug delivery conjugates containing unnatural amino acids and methods for using
WO2014057432A3 (en) Multicomponent lipid nanoparticles and processes for the preparation thereof
WO2016004048A3 (en) Targeted conjugates and particles and formulations thereof
EP2552439A4 (en) Methods of enhancing drug delivery and effectiveness of therapeutic agents
IL223783B (en) Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
EP2782632A4 (en) Myocardial drug delivery apparatus and methods
IL222120A (en) (indol-1-yl)-carbonylalkyl derivatives, process for their preparation, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating cancer
PL2299977T3 (en) Liposomes for drug delivery and methods for preparation thereof
EP2493475A4 (en) Methods and cosmetic preparations for the sustained delivery of therapeutic agents to the eye
MX355833B (en) Method and formulation for inhalation.
EP2522338A4 (en) Polymer nanoparticle injection formulation composition containing rapamycin with improved water solubility, preparation method thereof, and anticancer composition for combined use with radiotherapy
EP2600876A4 (en) Combined drug delivery methods and apparatus
WO2010083337A3 (en) Composite nanostructures and methods for making and using them
EP2782631A4 (en) Implantable solid-liquig drug delivery apparatus, formulations, and methods of use
BR112013011480A2 (en) cancer treatment method, method of enhancing the therapeutic effectiveness of an anticancer drug, pmo1183 or a pharmaceutically acceptable salt thereof, use thereof and kit for use in cancer treatment
IL207546A0 (en) Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases
WO2011143201A3 (en) Ratiometric combinatorial drug delivery
IL206080A0 (en) Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases
WO2012040331A3 (en) Multistage nanoparticles
WO2011055980A3 (en) Composite of a protein comprising zinc oxide-bonding peptides and zinc oxide nanoparticles, and use thereof
EP2217063A4 (en) Thiolated paclitaxels for reaction with gold nanoparticles as drug delivery agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12803296

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12803296

Country of ref document: EP

Kind code of ref document: A2